parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in myonuclei	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	3 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 14907

receipt 14915: NEO1 in dopamine neurons, braak

power: full sample +0.00 (p 0.990, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.01 (p 0.976, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.01 (p 0.976, n 18). could be the mix.
skeptic: leave-one-out range -0.12 to +0.12, sign flips 6; without severely affected donors +0.00 (p 0.990, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NEO1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 14914: NEO1 in oligodendrocytes, braak

power: full sample +0.08 (p 0.767, n 18), 95% CI -0.41 to +0.52. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.06 (p 0.820, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.08 (p 0.767, n 18). could be the mix.
skeptic: leave-one-out range -0.04 to +0.20, sign flips 5; without severely affected donors +0.08 (p 0.767, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NEO1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts